MedTrace Logo

Adaptive Responses to Overfeeding and Weight

NCT03857048 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2023-04-07

No results posted yet for this study

Summary

To more effectively address the problem of weight regain following weight loss for obese individuals, this study will evaluate the underlying biology of the reduced obese state. In depth studies of appetite, energy expenditure, physical activity levels and fat metabolism will be completed in obese and reduced obese individuals; with the latter subdivided into those who have lost weight with diet alone or diet plus exercise. Individuals will be studied following a brief overfeeding period to better understand how differences in biological responses to overeating might be involved in promoting or protecting against weight gain.

Conditions

Interventions

OTHER

Weight Loss

12-wk weight loss intervention using a meal replacement strategy (Health \& Nutrition Technology, Carmel, CA), with an 8-10% weight loss goal

OTHER

Exercise training

16-wk supervised endurance exercise training program

OTHER

Overfeeding

3-day hypercaloric diet designed to overfeed by 40% above total daily energy requirements

Sponsors & Collaborators

  • University of Colorado, Boulder

    collaborator OTHER

  • University of Colorado, Denver

    lead OTHER

Principal Investigators

  • Daniel Bessesen, MD · University of Colorado Anschutz Health and Wellness Center

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-02-15
Primary Completion
2024-01-01
Completion
2024-01-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03857048 on ClinicalTrials.gov